Glenmark Pharma Gets US FDA Nod for Fluticasone Propionate Nasal Spray

Glenmark Pharmaceuticals Limited has received U.S. FDA approval for its Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray. This product is bioequivalent and therapeutically equivalent to Flonase® Nasal Spray, 0.05 mg/spray, a reference drug by Haleon US Holdings LLC. The nasal spray will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA. The market for Flonase® Nasal Spray achieved approximately $295.2 million in annual sales for the 12 months ending June 2026, according to IQVIA® sales data. This approval signifies an expansion of Glenmark's respiratory portfolio in the U.S., aiming to provide affordable treatment options.